JG

Jeevankumar Ganeshmal Bohra

Active Director Director DIN 01728678
DIN 01728678 First appointment Nov 2007 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2007
Shareholding value β€’β€’β€’β€’ Premium profile

About Jeevankumar Ganeshmal Bohra

Data last updated:

Jeevankumar Ganeshmal Bohra is a Director at Sinaria Pharmaceuticals Private Limited (since 2007). The company operates in Pharma.

DIN 01728678
Primary Designation Director
Industry Pharma
First Appointment 27 Nov 2007
Oldest Company Age 18 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Nov 20072007Active

Directorship timeline

Open interactive timeline →
Sinaria Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jeevankumar Ganeshmal Bohra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jeevankumar Ganeshmal Bohra

Jeevankumar Ganeshmal Bohra currently holds 1 directorship: Sinaria Pharmaceuticals Private Limited (Director, since 27 Nov 2007).

Jeevankumar Ganeshmal Bohra was first appointed on 27 Nov 2007 as Director at Sinaria Pharmaceuticals Private Limited.

The current boards of Jeevankumar Ganeshmal Bohra's companies include Ashwin Raichand Shah (Sinaria Pharmaceuticals Private Limited), Avani Ashwin Shah (Sinaria Pharmaceuticals Private Limited), Meena Mahesh Shah (Sinaria Pharmaceuticals Private Limited), Raychand Kanji Shah (Sinaria Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available